Skip to main content
. 2023 Jul 3;6(7):943–969. doi: 10.1021/acsptsci.3c00047

Table 11. mRNA Vaccines in Phase 2 or More Advanced Clinical Trials for Cancersa.

Vaccine name CAS Registry Number Disease indication Antigen Company
Autogene cevumeran 2365453-34-3 Melanoma; colorectal cancer Patient-specific neoantigens BioNTech
mRNA 4157 2741858-84-2 Melanoma Up to 34 neoantigens Moderna
mRNA 4359 2900354-08-5 Melanoma; non-small-cell lung carcinoma IDO and PD-L1 Moderna
BNT 111 2755828-88-5 Melanoma Mix of four melanoma-associated antigens BioNTech
BNT 112 2900354-09-6 Prostate cancer Mix of five prostate cancer-specific antigens BioNTech
BNT 113 2882951-85-9 PV16+ head-and-neck squamous carcinoma HPV16-derived tumor antigens (oncoprotein E6 and E7) BioNTech
CV 9202 1665299-76-2 Non-small-cell lung cancer NY-ESO-1, MAGE C1, MAGE C2, TPBG (5T4), survivin, MUC1 CureVac
CV 9103 2882951-83-7 Prostate cancer Mix of four prostate cancer-associated antigens CureVac
SW 1115C3 2882951-82-6 Non-small-cell lung cancer; esophageal cancer Patient-specific neoantigens Stemirna Therapeutics
Rocapuldencel T; AGS 003 2396421-01-3 Non-small-cell lung cancer; lung cancer; bladder and renal cancer Autologous tumor antigen and CD40L-loaded dendritic cell immunotherapy Argos Therapeutics
a

Data from the CAS Content Collection, Clinicaltrials.gov, and Pharmaprojects.